BioCatalyst

Remigromig, Ranibizumab — catalyst calendar

1 verified catalyst event(s) referencing Remigromig, Ranibizumab, each linked to its official source. Verified as of 2026-10-29.

Upcoming

DateEventCompanyDrugOfficial source & verification
2027-03-01
in 4mo
ESTIMATED
 READOUT
A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in
Phase 2/3 · Diabetic Macular Edema (DME)
 EyeBiotech Ltd. Remigromig, Ranibizumab ClinicalTrials.gov ↗
✓ Source-checked 2026-10-29
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.